Table 1.

Romiplostim study and retrospective patients characteristics

Characteristic	Romiplostim, N (%)	Retrospective, N (%)
Number of patients (total)	59	853
Age, median (range)	63 (24-75)	60 (19-80)
Sex
Male	34 (58)	503 (59)
Female	25 (42)	350 (41)
Disease
Multiple myeloma	40 (68)	484 (57)
NHL or HL	19 (32)	369 (43)
Conditioning regimen
Melphalan	40 (68)	484 (57)
BEAM	16 (27)	296 (35)
TBC	3 (5)	73 (8)
CD34+ cell dose (× 10E6/kg), median (range)	5.2 (2.9-8.7)	5.1 (1.47-16.3)

BEAM, carmustine, etoposide, cytarabine, melphalan; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; TBC, thiotepa, busulfan, cyclophosphamide.